Copy

Newsletter 12 - February 2016







COMBACTE on International Research Agenda

While we continuously work to improve our capacities to deliver high-quality studies, counteracting the immediate and future threats of antibiotic resistance, we are also thinking how our network organization will “survive” after the IMI funding period. I am, delighted to convey that “the future of COMBACTE” has entered the agenda of international research organizations. Read more..









REJUVENATE Study Update

Regulatory and Ethics submissions for Spain, France and Germany were completed in January 2016. With recruitment start into REJUVENATE planned for the end of March 2016, CTC Cologne is currently preparing the REJUVENATE investigator meeting, in Frankfurt, Germany. Read more..









COMBACTE at SRLF Paris

COMBACTE was at the annual congres of the, Société de Réanimation de Langue Française, Réanimation 2016, which was held from the 13th - 15th of January in Paris. There was considerable interest at the booth; new contacts were made with potential new investigator sites for CLIN-Net. Read more..








CLIN-Net Coordinator Meeting

The 2nd CLIN-Net national coordinators meeting took place in Grindelwald, Switzerland. Coordinators from 16 different countries discussed progress and future plans of the network. The program included a presentation of the EURECA study in COMBACTE-CARE by professor Jesús Rodriguez Baño. Read more..




 





ASPIRE-ICU Update

The ASPIRE-ICU team is continuously starting up centers and enrolling patients. Currently 7 Site Initiation Visits have been completed, 4 sites have started enrolling, with three sites in the study-phase of the trial and one site in the run-in phase. In January the first ASPIRE-ICU newsletter was published . Read more..




 

More news


 


Please contact the PMO team with your ideas for the next newsletter.
Click here to send us your thoughts! Looking forward to hearing from you!





Unsubscribe from this newsletter.

This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.

Email Marketing Powered by Mailchimp